Literature DB >> 22076833

Oral low-dose chemotherapy: successful treatment of an alveolar rhabdomyosarcoma during pregnancy.

Meinolf Siepermann1, Ewa Koscielniak, Tobias Dantonello, Dirk Klee, Joachim Boos, Barbara Krefeld, Arndt Borkhardt, Thomas Hoehn, Alexzander Asea, Rüdiger Wessalowski.   

Abstract

We report for the first time the impact of neoadjuvant oral low-dose chemotherapy consisting of oral trofosfamide, idarubicin, and etoposide (O-TIE) in the case of alveolar rhabdomyosarcoma (RMS) in the lower jaw of an 18-year-old woman at 27 weeks of gestation, without fetal complications and a highly efficient anti-tumor response. Our study suggests the possible application of O-TIE treatment in a neoadjuvant setting during pregnancy and recommends a schedule that can be considered for the treatment of patients with high-risk sarcomas who cannot be treated with intensive chemotherapy for various reasons.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22076833      PMCID: PMC3138827          DOI: 10.1002/pbc.22934

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  20 in total

Review 1.  High-time chemotherapy or high time for low dose.

Authors:  B A Kamen; E Rubin; J Aisner; E Glatstein
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

2.  Soft tissue sarcoma in children: prognosis and management.

Authors:  Ewa Koscielniak; Mary Morgan; Jörn Treuner
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

3.  Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.

Authors:  Thomas Klingebiel; Joachim Boos; Florian Beske; Erika Hallmen; Christoph Int-Veen; Tobias Dantonello; Joern Treuner; Helmut Gadner; Ildiko Marky; Bernarda Kazanowska; Ewa Koscielniak
Journal:  Pediatr Blood Cancer       Date:  2008-04       Impact factor: 3.167

Review 4.  Cancer in pregnancy: gaps, challenges and solutions.

Authors:  David Pereg; Gideon Koren; Michael Lishner
Journal:  Cancer Treat Rev       Date:  2008-03-04       Impact factor: 12.111

5.  Transient neonatal myelosuppression after fetal exposure to maternal chemotherapy. Case report and review of the literature.

Authors:  Floris E A Udink ten Cate; Christine H ten Hove; Wendy M L E Nix; Johanna I P de Vries; Arjan A van de Loosdrecht; Ruurd M van Elburg
Journal:  Neonatology       Date:  2008-09-12       Impact factor: 4.035

6.  Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients.

Authors:  N Germann; F Goffinet; F Goldwasser
Journal:  Ann Oncol       Date:  2004-01       Impact factor: 32.976

7.  Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients.

Authors:  Iyad Sultan; Ibrahim Qaddoumi; Sameer Yaser; Carlos Rodriguez-Galindo; Andrea Ferrari
Journal:  J Clin Oncol       Date:  2009-04-27       Impact factor: 44.544

8.  Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes.

Authors:  Kristel Van Calsteren; Liesbeth Heyns; Frank De Smet; Liesbet Van Eycken; Mina Mhallem Gziri; Willemijn Van Gemert; Michael Halaska; Ignace Vergote; Nelleke Ottevanger; Frédéric Amant
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544

9.  Maternal and fetal outcome after invasive cervical cancer in pregnancy.

Authors:  D Zemlickis; M Lishner; P Degendorfer; T Panzarella; S B Sutcliffe; G Koren
Journal:  J Clin Oncol       Date:  1991-11       Impact factor: 44.544

Review 10.  Use of chemotherapy during human pregnancy.

Authors:  Elyce Cardonick; Audrey Iacobucci
Journal:  Lancet Oncol       Date:  2004-05       Impact factor: 41.316

View more
  2 in total

Review 1.  Bone and soft tissue sarcomas during pregnancy: A narrative review of the literature.

Authors:  George Zarkavelis; Dimitrios Petrakis; George Fotopoulos; Sotirios Mitrou; Nicholas Pavlidis
Journal:  J Adv Res       Date:  2016-02-02       Impact factor: 10.479

2.  Etoposide damages female germ cells in the developing ovary.

Authors:  Agnes Stefansdottir; Zoe C Johnston; Nicola Powles-Glover; Richard A Anderson; Ian R Adams; Norah Spears
Journal:  BMC Cancer       Date:  2016-08-11       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.